The evaluation of theraputic effects for advanced renal cell carcinoma patients using axitinib; dose intensity, gene polymorphism and micro vascular density

The evaluation of theraputic effects for advanced renal cell carcinoma patients using axitinib; dose intensity, gene polymorphism and micro vascular density - The evaluation of theraputic effects for advanced renal cell carcinoma patients using axitinib

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009833

Enrollment

Registered

2013-01-22

Start date

2013-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Renal Cell Carcinoma

Interventions

measrument dose intensity using axitinib and measurment gene polymorphism

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) over 20yrs 2) advanced RCC patients (cTxN1-2M0-1) need general treatment 3) ECOG PS0,1 4) suitable organ function liver,kidney, hematolgy 5) noemal herat function LVEF >70% 6) Pts had target lesions difiend vy RECIST ver1.1 7) Pts had informed and concent

Exclusion criteria

Exclusion criteria: unfit eligible criteria 1)ptotein uria 2+< 2)Pts had another cancers 3)Pts had myocardial infarction, pulumonary embolisim, brain infarction, heart failure, TIA, CABG within 6 months 4) pregnant

Design outcomes

Primary

Measure	Time frame
dose intensity, gene polymorphism and micro vascular density with axitinib	—

Secondary

Measure	Time frame
clinical response using RECIST ver4.0, adverse event using CTCAE ver4.0, mapping in pathology	—

Countries

Japan

Contacts

Public ContactTakashi Koyama

Nagoya University soumu-ka

ethics@med.nagoya-u.ac.jp052-744-1901

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026